ACURATE Enhance Post Market Study
← catalyst calendarSponsored by Boston Scientific Corporation (industry) · BSX — their whole pipeline →.
Phase
—
Status
Withdrawn
Study type
Observational
Enrollment
0actual
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
Boston Scientific made the decision to discontinue worldwide commercialization of the ACURATE valve platform.
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | May 2025 | estimated | When the study began enrolling |
| Primary completion | Dec 2025 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Apr 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2025-05-07 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-06-24 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Aortic Valve Stenosis
- Aortic Valve Calcification
- Aortic Diseases
Intervention
- Device: Transcatheter Aortic Valve Implantation/Replacement
Primary outcome
what the primary-completion date above is the date OFPrimary Endpoint:
measured Index procedure
Permalink · BSX's whole pipeline · Catalyst calendar · Every registered study · What changed